Literature DB >> 14704765

Dendritic cells: emerging pharmacological targets of immunosuppressive drugs.

Holger Hackstein1, Angus W Thomson.   

Abstract

Immunosuppressive drugs have revolutionized organ transplantation and improved the therapeutic management of autoimmune diseases. The development of immunosuppressive drugs and understanding of their action traditionally has been focused on lymphocytes, but recent evidence indicates that these agents interfere with immune responses at the earliest stage, targeting key functions of dendritic cells (DCs). Here, we review our present understanding of how classical and new immunosuppressive agents interfere with DC development and function. This knowledge might provide a rational basis for the selection of immunosuppressive drugs in different clinical settings and for the generation of tolerogenic DCs in the laboratory.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14704765     DOI: 10.1038/nri1256

Source DB:  PubMed          Journal:  Nat Rev Immunol        ISSN: 1474-1733            Impact factor:   53.106


  156 in total

Review 1.  Dendritic cells and regulation of graft-versus-host disease and graft-versus-leukemia activity.

Authors:  Elizabeth O Stenger; Hēth R Turnquist; Markus Y Mapara; Angus W Thomson
Journal:  Blood       Date:  2012-03-07       Impact factor: 22.113

Review 2.  How tolerogenic dendritic cells induce regulatory T cells.

Authors:  Roberto A Maldonado; Ulrich H von Andrian
Journal:  Adv Immunol       Date:  2010       Impact factor: 3.543

3.  Curcumin induces maturation-arrested dendritic cells that expand regulatory T cells in vitro and in vivo.

Authors:  N M Rogers; S Kireta; P T H Coates
Journal:  Clin Exp Immunol       Date:  2010-12       Impact factor: 4.330

Review 4.  Regulatory dendritic cells for human organ transplantation.

Authors:  Angus W Thomson; Diana M Metes; Mohamed B Ezzelarab; Dalia Raïch-Regué
Journal:  Transplant Rev (Orlando)       Date:  2019-05-13       Impact factor: 3.943

5.  High PD-L1/CD86 MFI ratio and IL-10 secretion characterize human regulatory dendritic cells generated for clinical testing in organ transplantation.

Authors:  Alan F Zahorchak; Camila Macedo; David E Hamm; Lisa H Butterfield; Diana M Metes; Angus W Thomson
Journal:  Cell Immunol       Date:  2017-09-14       Impact factor: 4.868

6.  Combinatorial delivery of immunosuppressive factors to dendritic cells using dual-sized microspheres.

Authors:  Jamal S Lewis; Chris Roche; Ying Zhang; Todd M Brusko; Clive H Wasserfall; Mark Atkinson; Michael J Clare-Salzler; Benjamin G Keselowsky
Journal:  J Mater Chem B       Date:  2014-05-07       Impact factor: 6.331

Review 7.  Regulatory myeloid cells in transplantation.

Authors:  Brian R Rosborough; Dàlia Raïch-Regué; Heth R Turnquist; Angus W Thomson
Journal:  Transplantation       Date:  2014-02-27       Impact factor: 4.939

8.  Dendritic cells treated with resveratrol during differentiation from monocytes gain substantial tolerogenic properties upon activation.

Authors:  Urban Svajger; Natasa Obermajer; Matjaz Jeras
Journal:  Immunology       Date:  2009-11-25       Impact factor: 7.397

9.  Histone deacetylase inhibition modulates indoleamine 2,3-dioxygenase-dependent DC functions and regulates experimental graft-versus-host disease in mice.

Authors:  Pavan Reddy; Yaping Sun; Tomomi Toubai; Raimon Duran-Struuck; Shawn G Clouthier; Elizabeth Weisiger; Yoshinobu Maeda; Isao Tawara; Oleg Krijanovski; Erin Gatza; Chen Liu; Chelsea Malter; Paolo Mascagni; Charles A Dinarello; James L M Ferrara
Journal:  J Clin Invest       Date:  2008-07       Impact factor: 14.808

10.  IL-1beta-driven ST2L expression promotes maturation resistance in rapamycin-conditioned dendritic cells.

Authors:  Heth R Turnquist; Tina L Sumpter; Allan Tsung; Alan F Zahorchak; Atsunori Nakao; Gerard J Nau; Foo Y Liew; David A Geller; Angus W Thomson
Journal:  J Immunol       Date:  2008-07-01       Impact factor: 5.422

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.